The same route question gets three different answers
A useful comparison keeps the substance, the route and the result on the same line.
Start with the actual route
Under the tongue, swallowed and injected describe different starting points. None of those words tells us how much of a substance reaches the blood or whether it helps a person.
I find it easier to start with a concrete question: does this experiment match the preparation being discussed? A paper can be interesting and still answer something else.
The same goes for the participants. A rat result stays a rat result. Changing “rats” to “people” in the explanation would skip the very work a human study needs to do.
Three findings, kept in their own lanes
| Substance | What was studied | What was measured |
|---|---|---|
| BPC-157 | Muscle and stomach routes in rats | Ulcer healing |
| CJC-1295 | Injections under the skin in healthy adults | Growth hormone and a related growth signal |
| Semaglutide | Injections in adults without diabetes: obesity, or overweight plus a weight-related health condition | Weight change |
The sources are the rat ulcer study, CJC-1295 human study and semaglutide weight trial. In FDA's review, the CJC-1295 material appears to have been the DAC form; its exact salt wasn't specified.
These aren't three entries in a best-peptide contest. They ask different questions. None of these experiments tests a human sublingual preparation.
What does “works” mean here?
Did it reach the blood? That needs measurements of the substance, rather than an assumption based on where it was placed.
Did it change a blood marker? The CJC-1295 study found higher hormone levels. That isn't the same finding as better sleep or recovery.
Did it improve a health outcome? The semaglutide trial found greater average weight loss than placebo, with lifestyle support in both groups. That result belongs to those participants and that studied injection.
A fair comparison needs to ask the same kind of question on both sides. Otherwise, the neatness of a table can hide how much has changed between its rows.
A prescription adds another question
For an individual, a care conversation also needs to cover the exact preparation, possible harms and what remains unknown. A route sounding convenient doesn't settle those points.
FDA explains why compounded medicines aren't FDA-approved. A prescription doesn't turn a missing route study into a completed one.
The longer pages on BPC-157, CJC-1295 and semaglutide keep the safety cautions beside the findings. That's where a comparison becomes useful: a clearer account of what each result can actually tell you.